title: [Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced non-small cell lung cancer: a multi-center retrospective study].
abstract: BACKGROUND
  The aim of this study is to detect the efficacy and toxicity of gemcitabine and vinorelbine (GN as second-line or further-line treatment) in refractory advanced non-small cell lung cancer (NSCLC) patients in China.
  
  
  METHODS
  We retrospectively reviewed 53 NSCLC patients treated with this agent at four hospital in China from Jan 01, 2004 to Jun 30, 2010. Survival analysis was evaluated by Kaplan-Meier method.
  
  
  RESULTS
  A total of 53 patients were analyzed in this study (28 patients in second-line and 25 in third- or further-line treatment). The objective response rate (ORR) was 9.4%. The disease control rate (DCR) was 56.6%. The progression-free survival (PFS) and median overall survival (OS) was 3.0 and 17.6 months, respectively. Univariate analysis, revealed performance status (PS) score was an independent prognostic factor for overall survival.
  
  
  CONCLUSIONS
  The GN agent is effective for the second-line or further-line treatment in advanced non-small cell lung cancer. The toxicity is well tolerated .
authors.affiliation: Shanghai Lung Cancer Center, Chest Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200030, China. lushun1964@hotmail.com
authors.forename: Shun
authors.initials: S
authors.lastname: Lu
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Yu
authors.forename: Gongyan
authors.initials: G
authors.lastname: Chen
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002681:China; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine